Search Results
Jul 23, 2025, 17:31 ET Claudin 18.2-Directed Oncology Therapeutics--A Fast-Growing Market with Blockbuster Potential | DelveInsight
18.2 is a tight junction protein essential for preserving the integrity of the stomach lining. It is one of the two isoforms produced by the CLDN18 gene and is normally found only in differentiated epithelial cells of the gastric mucosa. In healthy tissues, Claudin 18.2 is hidden within tight junctions,
More news about: DelveInsight Business Research, LLP
Jul 23, 2025, 16:08 ET SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit
the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ELEVIDYS, a prescription gene therapy intended for certain patients being treated for Duchenne muscular dystrophy, posed significant safety risks to patients; (2) ELEVIDYS trial
More news about: THE ROSEN LAW FIRM, P. A.
Jul 23, 2025, 16:06 ET RCKT Class Action Reminder: Robbins LLP Reminds Rocket Pharmaceuticals, Inc. Investors of the Class Action Lawsuit - Contact us for more information
2025 and May 26, 2025. Rocket is a fully integrated, late-stage biotechnology company focused on the development of gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases.
More news about: Robbins LLP
Jul 23, 2025, 13:15 ET RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
2025. CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The Rocket Pharmaceuticals class action lawsuit alleges that
More news about: Robbins Geller Rudman & Dowd LLP
Jul 23, 2025, 09:00 ET Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping
designed to deliver phosphorodiamidate morpholino oligomers (PMOs) to skeletal muscle and heart tissue to specifically skip exon 44 of the dystrophin gene and enable production of near-full length dystrophin. "Breakthrough Therapy designation further underscores the FDA's appreciation for the significant
More news about: Avidity Biosciences, Inc.
Jul 22, 2025, 13:23 ET Analysis Group Co-Authors Examine the Advancements in and Application of Health Economics and Outcomes Research to the Evaluation of Cell and Gene Therapies for Rare Diseases
economics and outcomes research (HEOR), collaborated with Novartis to examine how HEOR is transforming the evaluation and access pathways for cell and gene therapies (CGTs) for rare diseases. As CGTs move from experimental to increasingly approved treatments for rare diseases, health systems face urgent
More news about: Analysis Group
Jul 22, 2025, 11:21 ET Weekly Earnings Decline for Second Consecutive Quarter, Ludwig Institute Reports
@LISEP_org. About Gene LudwigIn addition to his role as LISEP chair, Gene Ludwig is founder of the Promontory family of companies and Canapi LLC, a financial technology
More news about: Ludwig Institute for Shared Economic Prosperity
Jul 22, 2025, 10:21 ET Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets
KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and it's novel delivery systems to transform and improve the treatment of neurodegenerative and
More news about: Klotho Neurosciences, Inc.
Jul 22, 2025, 10:16 ET KROMATID Works With Consortium to Empower Cancer Genomics with Industry-Leading Sequencing Standards
approach. About KROMATIDKROMATID is a contract research organization (CRO) specializing in cytogenetic precision, empowering the cell and gene therapy community with advanced genomic integrity analysis solutions. Through our cutting-edge KROMASURE™ platform, we provide high-confidence,
More news about: KROMATID
Jul 22, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
action] On May 27, 2025, Rocket issued a press release "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease." The press release disclosed that "[a] patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected
More news about: Pomerantz LLP
Jul 22, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG
dystrophy ("DMD"), a genetic disorder characterized by progressive muscle degeneration and weakness. DMD is caused by the mutation of the dystrophin gene, resulting in, inter alia, a limited production of the dystrophin protein, which in turn leads to DMD's clinical features. According to PepGen,
More news about: Pomerantz LLP
Jul 22, 2025, 09:00 ET National Organization for Rare Disorders Announces New Board Members
Securities, where his work was concentrated on emerging life science tools and technologies such as AI-driven drug discovery, synthetic biology, and cell and gene therapy. His financial experience spans equity research and health care investment banking, advising both public and private companies on strategic
More news about: National Organization for Rare Disorders (NORD®)
Jul 22, 2025, 08:45 ET Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: Levi & Korsinsky, LLP
Jul 22, 2025, 08:19 ET Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins
liver histology, and metabolic markers.Arm 2: GDNF administered to TK-NOG human hepatocyte-engrafted mice — assessing human liver-specific gene expression, pathology, and glucose metabolism.All protocols are IRB-approved and comply with VA and federal research ethics standards.
More news about: Hoth Therapeutics, Inc.
Jul 22, 2025, 08:03 ET Solvias Expands U.S. Capabilities as RTP Center Becomes cGMP-Ready
global life sciences industry. Its expert team combines decades of experience with regulatory expertise across small molecules, biologics, and cell and gene therapies. Solvias offers end-to-end solutions from raw material testing to drug product release and API development for small molecules. Headquartered
More news about: Solvias/Water Street Healthcare Partners
Jul 22, 2025, 08:00 ET Unchained Labs drops Stunner AF and new Sunshine flavors to crush therapeutic nanoparticle development
July 22, 2025 /PRNewswire/ -- Unchained Labs, the life sciences company that's all about getting biologics and gene therapy researchers the right tool for the job, just dropped its latest power combo for therapeutic nanoparticle workflows —
More news about: Unchained Labs
Jul 22, 2025, 08:00 ET Unchained Labs drops Stunner AF and new Sunshine flavors to crush therapeutic nanoparticle development
July 22, 2025 /PRNewswire/ -- Unchained Labs, the life sciences company that's all about getting biologics and gene therapy researchers the right tool for the job, just dropped its latest power combo for therapeutic nanoparticle workflows —
More news about: Unchained Labs
Jul 22, 2025, 07:00 ET Nanoscope Therapeutics Publishes Mechanism of Action Details for Proprietary Broadband and Fast Multi-Characteristic Opsin Technology
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene therapies for patients suffering vision loss from retinal degenerative diseases, today announced the publication of a paper
More news about: Nanoscope Therapeutics
Jul 22, 2025, 03:52 ET METiS Technologies Showcases AI-Powered Nanodelivery Platform at the 2025 Controlled Release Society Annual Meeting
across multiple tissue targets: Liver-targeted LNPs developed through AiLNP demonstrated best-in-class performance for gene editing, achieving high efficiency and safety in NHPs. Using CRISPR-Cas9-mediated TTR knockdown as a model, LNP developed by AiLNP achieved ~90% reduction
More news about: METiS Technologies
Jul 22, 2025, 03:00 ET SkylineDx's Merlin Melanoma Assay shows its ability to reduce SLNB by over 40% in a Danish Multicenter Validation Study
prediction model for cutaneous melanoma patients and is the only commercially available GEP test that combines clinicopathologic (CP) variables with gene expression profiling (GEP) into a single integrated algorithm. This CP-GEP model is also the only GEP test that provides a binary stratification of
More news about: SkylineDx
Jul 21, 2025, 16:06 ET SHAREHOLDER ALERT: Berger Montague Reminds Rocket Pharmaceuticals (NASDAQ: RCKT) Investors of Class Action Lawsuit Deadline
CLICK HERE. Rocket Pharmaceuticals, headquartered in Cranbury, New Jersey, specializes in gene therapies for rare and life-threatening diseases. The lawsuit claims the Company failed to disclose major safety-related updates to its RP-A501
More news about: Berger Montague
Jul 21, 2025, 09:00 ET Minaris Advanced Therapies Welcomes Orla Cloak as Chief Executive Officer
Advanced Therapies is a global contract development and manufacturing organization (CDMO) and contract testing provider focused exclusively on Cell and Gene therapies. Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania, and has more than 650,000 square
More news about: Minaris Advanced Therapies, LLC
Jul 21, 2025, 09:00 ET Minaris Advanced Therapies Welcomes Orla Cloak as Chief Executive Officer
Advanced Therapies is a global contract development and manufacturing organization (CDMO) and contract testing provider focused exclusively on Cell and Gene therapies. Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania, and has more than 650,000 square
More news about: Minaris Advanced Therapies, LLC
Jul 21, 2025, 08:45 ET Shareholders of Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights - SRPT
during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: The Gross Law Firm
Jul 21, 2025, 07:00 ET Synthego Announces Successful Close of Acquisition by Perceptive Advisors
and supports the development of CRISPR-based therapies for the global market. Synthego launched a GMP offering of SpCas9 in May and recently expanded gene editing options with launches of eSpOT-ON and Accubase™ enzymes in July, along with related guide RNA offerings. "We're incredibly excited about
More news about: Synthego